Dwight Moxie is VP & Secretary at Revance Therapeutics, Inc. (RVNC). They have made 5 open-market trades across 1 company since 2021, most recently 2025-02-06.
CIK 0001803375
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RVNC | 18,125 | $66K |
Shares reported on the most recent Form 4, priced at the 2025-02-06 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RVNC | SELL | 2024-03-18 | 2024-03-19 | $5.04 | $41K | -3.1% | -22.3% | -42.6% |
| RVNC | SELL · 10b5-1 | 2023-09-05 | 2023-09-07 | $17.67 | $1.0M | -16.3% | -38.4% | -57.3% |
| RVNC | SELL | 2023-05-15 | 2023-05-16 | $34.55 | $1.5M | -8.7% | -14.0% | -41.7% |
| RVNC | SELL | 2023-03-09 | 2023-03-09 | $31.59 | $1.2M | +7.2% | +2.9% | +5.1% |
| RVNC | SELL | 2022-09-14 | 2022-09-16 | $27.07 | $298K | -3.1% | -4.2% | -16.4% |
| RVNC | SELL | 2021-09-27 | 2021-09-28 | $30.00 | $50K | -6.6% | -52.1% | -41.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.